Clinical Efficacy and Cost-Effectiveness of the Triglycerides and Glucose Index

Because the increasing trends in the obesity prevalence, which closely mirrors the increase of insulin resistance and the consequent development of metabolic disorders and cardiovascular risk factors. The body of evidence unequivocally show that insulin resistance is associated to prediabetes, diabetes, hypertension, atherosclerosis, metabolic syndrome, some types of cancer, and non-alcoholic fatty liver disease. So, changes on lifestyle such as a health customary diet and routine physical activity for preventing or the management of obesity are priorities to improve the health status. With this regard, the early detection of insulin resistance holds as important public health issue. In this book, we review evidence regarding the efficacy of the Triglycerides and Glucose (TyG) index for measuring insulin resistance in the clinical setting, as well as the cost-effectiveness analysis of the index. The review is focused on the efficacy of TyG index in the metabolic glucose disorders, cardiovascular disease, some types of cancer, as well as in the children and adolescents. Also, we present data about the cost-effectiveness of the TyG index as compared with the Homeostatic Model Assessment for Insulin Resistance index. For a better understanding the initial chapters display the concept of insulin resistance and the clinical validated tests for its measuring. Hence, the aimed objective was to evaluate the clinical efficacy and cost-effectiveness of using TyG index for diagnosing insulin resistance in the clinical setting.